Clinical Trial Update: Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluated methyl B12 (methylcobalamin) for behavioral and metabolic outcomes in children with autism; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Methyl B12 (methylcobalamin)

Snippet

Sponsor: University of California, San Francisco | Conditions: Autistic Disorder | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-02-24